Standard BioTools
Standard BioTools (NASDAQ: LAB) designs mass cytometry, Imaging Mass Cytometry, and microfluidic genomics instruments, consumables, and lab services for pharma, biotech, academic, clinical, and agrigenomics customers globally, and is merging with Treeline Biosciences in 2026.
- Company typePublic
- Founded1999
- HeadquartersSouth San Francisco, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Standard BioTools firmographics
Firmographics- Name
- Standard BioTools
- Legal name
- Standard BioTools Inc.
- Website
- https://standardbio.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Standard BioTools (NASDAQ: LAB) designs mass cytometry, Imaging Mass Cytometry, and microfluidic genomics instruments, consumables, and lab services for pharma, biotech, academic, clinical, and agrigenomics customers globally, and is merging with Treeline Biosciences in 2026.
- Ownership category
- akta.pro rank
Standard BioTools industry classification
Industry- Product category
- Life Sciences Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)
- akta.pro secondary industries
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Standard BioTools is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Standard BioTools business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Instruments: Sale of capital equipment including CyTOF systems, Hyperion imaging systems, and Biomark genomics systems. These are high-value instruments with typical enterprise sales cycles.
- Consumables: Recurring revenue from antibodies, reagents, IFC chips, panels, and assay kits. Q1 2026 showed 35% growth in consumables revenue, indicating strong recurring revenue base.
- Lab Services: Fee-for-service laboratory work where Standard BioTools runs samples for customers using their platforms, providing data as a service offering.
- Licensing Royalties: 2% royalty on SOMAmer-based NGS library preparation kit revenues for 10 years retained from the SomaLogic sale to Illumina, plus co-exclusive license to Single SOMAmer IP.
- Earnout Payments: Up to $75 million in additional earnout payments tied to 2025 and 2026 performance targets from the SomaLogic sale.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Instrument systems (CyTOF XT PRO, Hyperion XTi, Biomark X9) sold as capital equipment with enterprise pricing |
| Unit Pricing | Pay-as-you-go | Reagent and antibody catalog with over 800 antibodies and 300+ metal-labeled antibodies |
| Usage-based | Pay-as-you-go | Lab Services for sample processing and analysis |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Standard BioTools product offering
Product offeringCore offering
Standard BioTools designs, manufactures, and sells precision life sciences instruments and consumables for multi-omics research. Its core platform comprises three proprietary instrument systems—the CyTOF XT PRO mass cytometer for single-cell proteomics, the Biomark X9 System for high-throughput microfluidics-based genomics (PCR, qPCR, NGS library prep), and the Hyperion XTi Imaging System for Imaging Mass Cytometry spatial proteomics—supported by a consumables catalog of metal-labeled Maxpar antibodies, Integrated Fluidic Circuits, custom reagents, and a Lab Services offering that runs customer samples on its platforms.
Product overview
Standard BioTools is a life sciences tools company providing precision genomic and proteomic solutions through a platform-plus-modules architecture. The core portfolio centers on three instrument systems: the Biomark X9 System for high-throughput microfluidics-based genomics (real-time PCR and NGS library prep), the CyTOF XT PRO system for mass cytometry-based single-cell proteomics, and the Hyperion XTi Imaging System for Imaging Mass Cytometry spatial proteomics. These platforms are complemented by an extensive consumables ecosystem including Maxpar metal-labeled antibodies (800+ catalog items), Integrated Fluidic Circuits (IFCs), and specialized panels such as the Maxpar Direct Immune Profiling Assay and LyoMax lyophilized panels. Software tools including CyTOF Panel Designer, MCD Viewer, and analysis software support instrument operation and data workflows. Services include custom antibody conjugation, D3 genomic assay design, and laboratory services. The company historically operated the SomaScan proteomics platform through its SomaLogic subsidiary, which was sold to Illumina in January 2026.
Differentiator
Problem solved
Functional benefit
Brands
- CyTOF: Mass cytometry technology platform for single-cell proteomics analysis
- Hyperion
- Biomark
- Maxpar
- Advanta
- SomaScan
Products and services
- Biomark X9 System High-throughput genomics platform for real-time PCR and next-generation sequencing library preparation using microfluidics-based integrated fluidic circuits (IFCs). The only automated walk-away PCR/qPCR/NGS library prep system on the market, enabling up to 9,216 reactions per run with minimal sample and reagent consumption and 96x less reagents compared to plate-based methods.
- CyTOF XT PRO system Advanced mass cytometry system for single-cell proteomics that analyzes immune responses at scale, capturing 50+ targets simultaneously including cell surface markers, signaling proteins, and cytokines with 21 CFR Part 11 compliance for clinical research. Designed for clinical trials with enhanced barcoding capabilities.
- Hyperion XTi Imaging System Imaging Mass Cytometry system for spatial proteomics that enables simultaneous analysis of 40+ protein and RNA markers on tissue sections at subcellular resolution with three imaging modes (Preview, Cell, Tissue) and automated slide loading for whole slide imaging.
- Lab Services Multi-omic services turning samples into high-quality data, including multiplexed tissue imaging with Hyperion XTi, single-cell analysis with CyTOF technology, and spatial proteomics with expert scientific team support. Lab Services support research at all top 20 pharmaceutical companies and operate globally with labs in Canada, Asia, and the US.
- Integrated Fluidic Circuits (IFCs) Precision-manufactured microfluidic chips including Flex Six, 48.48, 96.96, and 192.24 formats that automate molecular biology reactions in nanoliter volumes for various genomic applications. Consumables for the Biomark X9 and related genomics platforms.
- Maxpar Antibodies Catalog of over 800 metal-labeled antibodies detecting more than 400 unique human or mouse targets including cell-surface targets, cytokines, signaling proteins, and transcription factors for mass cytometry applications. Available via the Standard BioTools online catalog.
- Maxpar Antibody Conjugation Service Custom conjugation service that expands CyTOF panels by adding metal-labeled targets using 51 high-purity metal tags, with optional biochemical or biological confirmation testing for customer-specific research needs.
- D3 Assay Design Expert-guided custom genomic panel design service supporting SNP Type genotyping assays, Delta Gene expression assays, and targeted NGS assays with two-week average delivery time.
- Single SOMAmer Reagents Proprietary SOMAmer (Slow Off-rate Modified Aptamer) reagents enabling proteomics analysis. Standard BioTools retained rights to single SOMAmer commercialization following the January 2026 sale of SomaLogic to Illumina, maintaining capabilities in protein detection and analysis.
Quantifiable outcome
- Up to 135 cell surface and intracellular antigens can be quantified simultaneously
- +7 more outcomes
Companies that use Standard BioTools
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
Standard BioTools technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Standard BioTools partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Treeline BiosciencescoreReverse merger transaction valued at approximately $900 million, transforming Standard BioTools from a life sciences tools company into a clinical-stage biotechnology business. Combined entity will have over $900M in cash and be led by Treeline CEO Josh Bilenker. Expected to close H2 2026.
- Indiana University Genetics BiobankminorPartnership for SNP-based genetic fingerprinting workflows supporting sample identity and quality control in biobanking. The IUGB, with approximately 4.5 million specimens, utilizes Standard BioTools microfluidics platforms for DNA fingerprinting workflows to verify sample identity.
- Molecular InstrumentscoreCollaboration to develop advanced Imaging Mass Cytometry workflows incorporating HCR (Hybridization Chain Reaction) imaging technologies. The integration aims to improve sensitivity and flexibility by enabling amplified detection of RNA and protein markers, facilitating multi-omic analysis within a single workflow using the Hyperion Imaging System.
- Genomics EnglandcoreCollaboration with Illumina's Protein Prep solution for proteomics research supporting Genomics England's population health initiatives.
- Precision Health Research, Singapore (PRECISE-SG100K)coreCollaboration using SomaScan platform for large-scale population health study analyzing 100,000 samples. Represents Singapore's national effort to advance precision medicine through comprehensive proteomics profiling.
- IlluminacoreSale of SomaLogic subsidiary for $350M upfront plus up to $75M earnout. Standard BioTools retains 2% royalty on SOMAmer-based NGS library preparation kits for 10 years and co-exclusive license to Single SOMAmer IP. Post-sale, Illumina integrates SomaScan proteomics into its multiomics platform.
Scale indicators18 records
Recent moves8 records
Expansion highlights6 records
Standard BioTools competitors and assessment
Company assessmentDirect peers
- Cytek Biosciences: Spectral flow cytometry competitor offering high-parameter cell analysis instruments (Aurora, Northern Lights). Direct competitor to CyTOF in single-cell proteomics workflows serving pharma, academic and clinical research customers.
- 10x Genomics: Single-cell and spatial biology platform (Chromium, Visium/Xenium) competing head-to-head with Standard BioTools' Biomark and Hyperion products in multi-omics and spatial biology research markets.
- Akoya Biosciences: Spatial biology company with CODEX and PhenoCycler platforms that compete with Hyperion XTi in multiplexed tissue imaging for immuno-oncology and translational research applications.
Broad incumbents
- Becton, Dickinson and Company (BD): Life sciences tools incumbent with the BD FACSDiscover and broader flow cytometry portfolio. Competes with CyTOF in cell analysis and has a much larger installed base across pharma and academic labs.
- Bio-Rad Laboratories: Established life science tools company with the ZE5 cell analyzer and Bio-Plex multiplexed assay platforms. Competes with both Standard BioTools' flow/mass cytometry and genomics product lines.
- Thermo Fisher Scientific: Diversified life sciences tools giant offering flow cytometers, mass spectrometers and genomics instruments that overlap with CyTOF, Hyperion and Biomark, particularly through its specialty diagnostics and PPD clinical research services.
- Danaher (Beckman Coulter Life Sciences / Cytiva): Multi-platform life sciences conglomerate whose Beckman Coulter flow cytometry and Cytiva bioprocessing portfolios compete with Standard BioTools in research and translational lab markets.
Emerging players
- Mission Bio: Single-cell multi-omics company (Tapestri) focused on genomics + proteomics at single-cell resolution. Competes with CyTOF and Biomark for translational and clinical genomics research budget.
- Bruker Corporation: Mass spectrometry and analytical instruments vendor offering timsTOF and related cytometry-adjacent platforms that compete with CyTOF mass cytometry in proteomics research.
Others
- Illumina: Sequencing giant that acquired SomaLogic from Standard BioTools and now sells the Protein Prep solution, including the 40+ institutions Standard BioTools formerly served. Strategic counterparty and genomics ecosystem partner rather than a direct CyTOF competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Standard BioTools social profiles
Digital presenceStandard BioTools financial estimates
Financial estimateRevenue estimate
Valuation estimate
Standard BioTools leadership team
Management profileNumber of profiles
Profiles4 records
Standard BioTools subsidiaries and ownership
Company hierarchySubsidiaries2 records
Standard BioTools funding detail
Funding detailFunding overview
Funding rounds9 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Standard BioTools M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Standard BioTools
What does Standard BioTools do?
Standard BioTools designs, manufactures, and sells precision life sciences instruments and consumables for multi-omics research. Its core platform comprises three proprietary instrument systems—the CyTOF XT PRO mass cytometer for single-cell proteomics, the Biomark X9 System for high-throughput microfluidics-based genomics (PCR, qPCR, NGS library prep), and the Hyperion XTi Imaging System for Imaging Mass Cytometry spatial proteomics—supported by a consumables catalog of metal-labeled Maxpar antibodies, Integrated Fluidic Circuits, custom reagents, and a Lab Services offering that runs customer samples on its platforms.
Is Standard BioTools a public or private company?
Standard BioTools is a public company. It is classified as public and is currently operating.
When was Standard BioTools founded?
Standard BioTools was founded in 1999. It employs 501 to 1,000 people.
Where is Standard BioTools based?
Standard BioTools is headquartered in South San Francisco, United States, in the North America region.
How does Standard BioTools make money?
Five revenue lines are on record. Instruments are the primary driver. The others are consumables, lab Services, licensing Royalties and earnout Payments.
Who are Standard BioTools's main competitors?
Direct peers on record are Cytek Biosciences, 10x Genomics and Akoya Biosciences. Broad incumbents are Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Thermo Fisher Scientific and Danaher (Beckman Coulter Life Sciences / Cytiva). Emerging players are Mission Bio and Bruker Corporation. Illumina is listed as an others.
Does Standard BioTools have an API?
No public API is recorded for Standard BioTools.
What industry is Standard BioTools in?
Standard BioTools's product category is Life Sciences Instruments. Its primary akta.pro industry code is HLAGAIAB, Mass Spectrometry & Spectroscopy Instruments, with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3826.